CULLINAN THERAPEUTICS INC. - COMMON STOCK

Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting

26 5 2022 07:45:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference

19 5 2022 07:00:01 提供 Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results

16 5 2022 05:45:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl

12 5 2022 01:00:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 5 2022 16:10:24 提供 Nasdaq GlobeNewswire

Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting

27 4 2022 09:00:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences

05 4 2022 07:00:01 提供 Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 4 2022 15:34:22 提供 Nasdaq GlobeNewswire

Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients

28 3 2022 15:01:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

17 3 2022 06:08:06 提供 Nasdaq GlobeNewswire

Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022

17 3 2022 06:00:01 提供 Nasdaq GlobeNewswire

Cullinan Oncology to Present at the Barclays Global Healthcare Conference

09 3 2022 07:00:02 提供 Nasdaq GlobeNewswire

Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022

08 3 2022 16:30:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of Jeffrey Jones, M.D., MPH, MBA to Chief Medical Officer and Anne-Marie Martin Ph.D. to Board of Directors

28 2 2022 07:00:01 提供 Nasdaq GlobeNewswire

Cullinan Oncology to Present at SVB Leerink’s 11th Annual Global Healthcare Conference

07 2 2022 05:30:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment

10 1 2022 05:30:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology to Present at Upcoming Virtual Investor Conferences

05 1 2022 08:00:02 提供 Nasdaq GlobeNewswire

FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

04 1 2022 06:00:02 提供 Nasdaq GlobeNewswire

Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients

16 12 2021 05:30:00 提供 Nasdaq GlobeNewswire

Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients

13 12 2021 06:00:00 提供 Nasdaq GlobeNewswire